ARIAD Pharmaceuticals Inc (ARIA)

12.84
0.85 6.20
NASDAQ : Health Care
Prev Close 13.69
Open 13.25
Day Low/High 12.32 / 13.25
52 Wk Low/High 4.37 / 10.07
Volume 6.77M
Avg Volume 7.85M
Exchange NASDAQ
Shares Outstanding 194.20M
Market Cap 2.58B
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

ARIAD's Investigational Medicine Brigatinib Demonstrated 15.6 Month Systemic Median Progression-Free Survival In ALTA Study

ARIAD's Investigational Medicine Brigatinib Demonstrated 15.6 Month Systemic Median Progression-Free Survival In ALTA Study

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), a rare cancer-focused innovative biotechnology company, today announced clinical data on brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor, from...

ARIAD Announces Data Presentations At American Society Of Hematology Meeting

ARIAD Announces Data Presentations At American Society Of Hematology Meeting

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the results of clinical and translational studies on Iclusig ® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with...

ARIAD Presents Updated Brigatinib Data With 18.4 Months Median Intracranial Progression Free Survival (PFS) In ALK+ NSCLC Patients With CNS Metastases At The World Conference On Lung Cancer

ARIAD Presents Updated Brigatinib Data With 18.4 Months Median Intracranial Progression Free Survival (PFS) In ALK+ NSCLC Patients With CNS Metastases At The World Conference On Lung Cancer

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), a rare cancer-focused innovative biotechnology company, today announced clinical data on brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor, from...

ARIAD To Host Webcast And Conference Call On Brigatinib Data Presentations At The World Conference On Lung Cancer

ARIAD To Host Webcast And Conference Call On Brigatinib Data Presentations At The World Conference On Lung Cancer

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA), a rare cancer-focused innovative biotechnology company, today announced a conference call and webcast to discuss the clinical data presented on brigatinib, the Company's...

ARIAD Announces Data Presentations At The World Conference On Lung Cancer

ARIAD Announces Data Presentations At The World Conference On Lung Cancer

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), a rare cancer-focused innovative biotechnology company, today announced that clinical data on brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor,...

The Inaugural ALK+ Day Is November 15, During Lung Cancer Awareness Month. (Photo: Business Wire)

The Inaugural ALK+ Day Is November 15, During Lung Cancer Awareness Month. (Photo: Business Wire)

In recognition of this month's Lung Cancer Awareness Month, ARIAD Pharmaceuticals, Inc.

'Mad Money' Lightning Round: 'Health Care Is All Over the Map'

'Mad Money' Lightning Round: 'Health Care Is All Over the Map'

Jim Cramer urges caution with phamaceutical companies Supernus and Ariad

Jim Cramer's 'Mad Money' Recap: Markets Pivot From Shocked to Bullish

Jim Cramer's 'Mad Money' Recap: Markets Pivot From Shocked to Bullish

Jim Cramer explains the rotation, looks ahead to next week.

ARIAD Announces Phase 1/2 Trial Data On Investigational Drug Brigatinib Published In The Lancet Oncology

ARIAD Announces Phase 1/2 Trial Data On Investigational Drug Brigatinib Published In The Lancet Oncology

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced clinical data on its investigational anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, were published in The Lancet Oncology (Gettinger, S.

ARIAD Reports Third Quarter 2016 Financial Results

ARIAD Reports Third Quarter 2016 Financial Results

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the third quarter and first nine months of 2016.

Why Incyte's Shares Could Soon Hit $100

Why Incyte's Shares Could Soon Hit $100

The drug company reported strong earnings.

ARIAD To Present At The Jefferies 2016 London Healthcare Conference

ARIAD To Present At The Jefferies 2016 London Healthcare Conference

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Jefferies 2016 London Healthcare Conference.

ARIAD To Webcast Conference Call On Third Quarter 2016 Financial Results

ARIAD To Webcast Conference Call On Third Quarter 2016 Financial Results

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its third quarter 2016 financial results on Monday, November 7, 2016, before the market opens.

ARIAD Announces U.S. Food And Drug Administration Acceptance Of NDA Filing For Brigatinib

ARIAD Announces U.S. Food And Drug Administration Acceptance Of NDA Filing For Brigatinib

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the U.

SHAREHOLDER ALERT: Goldberg Law PC Announces An Investigation Of Ariad Pharmaceuticals Inc. And Advises Investors With Losses To Contact The Firm

SHAREHOLDER ALERT: Goldberg Law PC Announces An Investigation Of Ariad Pharmaceuticals Inc. And Advises Investors With Losses To Contact The Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Ariad Pharmaceuticals Inc.

Pardon Me, but I Have a Few Things to Say... Vertex, Biogen, Ariad, Sarepta

Pardon Me, but I Have a Few Things to Say... Vertex, Biogen, Ariad, Sarepta

More about Vertex' Debbie Downer gene, Biogen's Alzheimer's spin and Sarepta caught in drug launch purgatory.

ARIAD Announces Publication Of The Preclinical Profile Of Brigatinib In The Journal Clinical Cancer Research

ARIAD Announces Publication Of The Preclinical Profile Of Brigatinib In The Journal Clinical Cancer Research

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the publication of preclinical data on brigatinib, its investigational oral tyrosine kinase inhibitor in development for the treatment of patients with...

Ariad Pharmaceuticals (ARIA) Stock Downgraded at JMP Securities

Ariad Pharmaceuticals (ARIA) Stock Downgraded at JMP Securities

Ariad Pharmaceuticals' (ARIA) stock rating was decreased to 'market perform' at JMP Securities on Tuesday.

Analysts' Actions -- Chesapeake, McCormick, Time Warner, VF Corp. and More

Analysts' Actions -- Chesapeake, McCormick, Time Warner, VF Corp. and More

Here are Tuesday's top research calls, including upgrades for Chesapeake Energy, McCormick and Time Warner, and a downgrade for VF Corp.

Ariad Pharmaceuticals (ARIA) Stock Drops, JPMorgan Downgrades

Ariad Pharmaceuticals (ARIA) Stock Drops, JPMorgan Downgrades

Ariad Pharmaceuticals' (ARIA) stock rating was cut to 'underweight' at JPMorgan on Monday.

Analysts' Actions -- Kinder Morgan, AT&T, Verizon, 3M and More

Analysts' Actions -- Kinder Morgan, AT&T, Verizon, 3M and More

Here are Monday's top research calls, including upgrades for Kinder Morgan, Verizon and 3M, and a downgrade for AT&T.

'Mad Money' Lightning Round: United and Southwest Better Than JetBlue?

'Mad Money' Lightning Round: United and Southwest Better Than JetBlue?

Jim Cramer says he likes LUV and UAL, but JBLU is not a favorite.

Jim Cramer's 'Mad Money' Recap: American Express Is Back on a Growth Track

Jim Cramer's 'Mad Money' Recap: American Express Is Back on a Growth Track

Don't ignore a big shift for American Express and don't dig in your heels, says Jim Cramer.

ARIAD Reaffirms Commitment To Discovering And Developing Treatments For Patients With Rare Cancers

ARIAD Reaffirms Commitment To Discovering And Developing Treatments For Patients With Rare Cancers

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today acknowledged the receipt of a Congressional letter and reaffirmed its commitment to discovering and developing treatments for patients with rare cancers with the...

Why Ariad Pharmaceuticals (ARIA) Stock Is Sliding Today

Why Ariad Pharmaceuticals (ARIA) Stock Is Sliding Today

Senator Bernie Sanders (I-VT) and Representative Elijah Cummings (D-MD) sent a letter to Ariad Pharmaceuticals (ARIA) today questioning the company's drug pricing.

Pardon Me, but I Have a Few Things to Say... Trump, Bernie, Radius, Ariad

Pardon Me, but I Have a Few Things to Say... Trump, Bernie, Radius, Ariad

Why Trump is killing biotech stocks, the Shire-for-Radius rumor makes no sense and Bernie Sanders gets a tweeting lesson.

Trader's Daily Notebook: You Might Consider Selling Facebook

Trader's Daily Notebook: You Might Consider Selling Facebook

Do that if you like top ticking crowd favorites, but set a protective stop.